• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase I Doesn’t Faze Them

Phase I Doesn’t Faze Them

October 25, 2006
CenterWatch Staff

It was interesting to see Waltham, Mass.-based Parexel, a global contract research organization (CRO), remaining unfazed in the hot phase I clinical research market. Earlier this month, Parexel agreed to acquire California Clinical Trials and Behavioral and Medical Research for $65 million. A key part of the deal is a 51-bed phase I unit that would boost Parexel’s presence in the phase I market.

Parexel could have become gun shy about phase I last March, when it took some heat after a phase I trial it was conducting for biotech company TeGenero in a London hospital resulted in six cases of serious illness. TeGenero has since gone bankrupt...

In the past year, the phase I market has been marked by capacity constraints, acquisitions and some controversy that has contributed to shifts in market share. Following numerous legal and regulatory problems at its Florida phase I units, SFBC, a CRO, shut down its operations there in May and sold key assets, including a clinical laboratory, to Allied Research International of Canada.

A milestone deal in the phase I market came in June when Radiant Research sold eight units to phase I leader Covance for $65 million. Recently, and last week, Omaha, Neb.-based Qualia Clinical Services opened a new 160 bed phase I unit. And pharmaceutical company AstraZeneca has opened its first phase I unit in the U.S., in Wilmington, Del.

It is clear that phase I is a place that global CROs and sponsors have to be as they try to find ways to eliminate poor drug candidates before they enter larger and much more expensive phase II and III trials.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing